Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in Patients With Schizophrenia
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label study to determine the pharmacokinetics, safety and tolerability of
single ascending doses of lumateperone long-acting injectable formulation in patients with
schizophrenia. Patients will be enrolled in one of up to three cohorts. All patients will
receive oral lumateperone for 5 days, followed by a 5-day washout of oral lumateperone, then
followed by a single dose of lumateperone LAI.